Arrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the rights ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Detailed price information for Adc Therapeutics Sa (ADCT-N) from The Globe and Mail including charting and trades.

The importance of China as a growth market for pharma multinationals is underlined by the news that Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug under review for ...